Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Jahna C. Espinosa"'
Autor:
Deborah J. Tate, Lian G. Rajewski, Charles J. Decedue, Carolyn J. Henry, Brian K. Flesner, Jeffrey N. Bryan, Jahna C. Espinosa, Michael Baltezor, Sandra M. Bechtel, Kim A. Selting
Publikováno v:
Veterinary and Comparative Oncology. 16:650-657
Carriers used to solubilize taxane chemotherapy drugs cause severe hypersensitivity. Nanoparticle formulations can provide improved dissolution and bioavailability of taxanes. Thus, a nanoparticulate, excipient-free formulation of paclitaxel (CTI5201
Autor:
Maurie Markman, Holly J. Smith, Gary Johnson, Gere S. diZerega, D.S. McMeekin, Scott Weir, Michael Baltezor, Katherine F. Roby, Jo Wick, Christine B. Mackay, Holly Maulhardt, Kathleen M. Moore, Gregory A. Reed, Stephen K. Williamson, Thomas K. Schulz, Jahna C. Espinosa, Charles J. Decedue
Publikováno v:
Cancer Chemotherapy and Pharmacology. 75:1075-1087
This multicenter, open-label, dose-escalating, phase I study evaluated the safety, tolerability, pharmacokinetics and preliminary tumor response of a nanoparticulate formulation of paclitaxel (Nanotax®) administered intraperitoneally for multiple tr
Autor:
Jeffrey N. Bryan, Kristin K. Dank, Nicole A. Clarkson, Senthil R. Kumar, Jahna C. Espinosa, Kimberly Anne Selting, Sandra M. Axiak-Bechtel, Thomas J. Rosol, Charles J. Decedue
Publikováno v:
Investigational new drugs. 31(6)
Background Paclitaxel is an effective antimitotic agent in cancer treatment; however, one of its most common toxicities is hypersensitivity due to excipients used for water solubility. Nanoparticulate paclitaxel (Crititax®, CTI52010) is paclitaxel t